Tilray (NASDAQ:TLRY) Stock Price Up 8.4%

Tilray Inc (NASDAQ:TLRY) traded up 8.4% during mid-day trading on Tuesday . The company traded as high as $2.33 and last traded at $2.33. 24,620,889 shares changed hands during trading, an increase of 3% from the average session volume of 23,913,797 shares. The stock had previously closed at $2.15.

Tilray Price Performance

The stock’s fifty day moving average is $1.87 and its 200-day moving average is $2.00. The stock has a market capitalization of $1.84 billion, a PE ratio of -1.12 and a beta of 2.30. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.63 and a quick ratio of 0.99.

Insiders Place Their Bets

In related news, CFO Carl A. Merton acquired 20,000 shares of Tilray stock in a transaction on Friday, January 12th. The stock was bought at an average cost of $1.87 per share, for a total transaction of $37,400.00. Following the completion of the transaction, the chief financial officer now owns 20,000 shares of the company’s stock, valued at approximately $37,400. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Tilray news, CEO Irwin D. Simon bought 53,700 shares of Tilray stock in a transaction dated Friday, January 12th. The stock was acquired at an average cost of $1.88 per share, for a total transaction of $100,956.00. Following the completion of the transaction, the chief executive officer now directly owns 2,033,058 shares of the company’s stock, valued at $3,822,149.04. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Carl A. Merton bought 20,000 shares of Tilray stock in a transaction dated Friday, January 12th. The stock was acquired at an average price of $1.87 per share, with a total value of $37,400.00. Following the completion of the transaction, the chief financial officer now directly owns 20,000 shares of the company’s stock, valued at $37,400. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 96,300 shares of company stock worth $183,210. Company insiders own 0.68% of the company’s stock.

Institutional Investors Weigh In On Tilray

A number of hedge funds have recently modified their holdings of the business. Mercer Global Advisors Inc. ADV raised its position in shares of Tilray by 10.0% in the third quarter. Mercer Global Advisors Inc. ADV now owns 28,072 shares of the company’s stock valued at $77,000 after buying an additional 2,550 shares during the last quarter. Rhumbline Advisers increased its position in Tilray by 20.4% during the second quarter. Rhumbline Advisers now owns 15,464 shares of the company’s stock worth $48,000 after purchasing an additional 2,623 shares during the last quarter. CreativeOne Wealth LLC increased its position in Tilray by 8.0% during the third quarter. CreativeOne Wealth LLC now owns 40,591 shares of the company’s stock worth $112,000 after purchasing an additional 2,994 shares during the last quarter. State of Wyoming increased its position in Tilray by 17.0% during the fourth quarter. State of Wyoming now owns 24,561 shares of the company’s stock worth $66,000 after purchasing an additional 3,564 shares during the last quarter. Finally, Private Advisor Group LLC increased its position in Tilray by 6.1% during the second quarter. Private Advisor Group LLC now owns 73,033 shares of the company’s stock worth $114,000 after purchasing an additional 4,177 shares during the last quarter. 9.35% of the stock is currently owned by institutional investors and hedge funds.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.